Makers Laboratories Ltd has closed its trading window for insiders effective July 1, 2026, to comply with regulatory requirements ahead of its financial results announcement. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026, of the financial year 2026-27. This measure is mandated under the SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent potential insider trading during the sensitive period preceding financial disclosures.

The company stated that the specific date for the Board meeting to consider the unaudited financial results for Q1FY27 will be intimated to the stock exchange in due course. The closure applies to all designated insiders as defined under the SEBI regulations, prohibiting them from dealing in the company's securities during this period.

Key Details

The filing was submitted by Piyush Ajmera, Company Secretary and ACS 58712, on behalf of Makers Laboratories Ltd .

Makers Laboratories Limited reported a 78.5% decline in consolidated net profit to ₹235.13 lakh for the financial year ended March 31, 2026, compared to ₹749.07 lakh in the previous year, as total expenses rose to ₹13,115.51 lakh. The company's consolidated revenue from operations increased 16.4% to ₹14,059.48 lakh from ₹12,075.12 lakh in FY25. On a standalone basis, the entity swung to a net loss of ₹171.98 lakh for the year against a profit of ₹464.11 lakh in the prior year, while revenue grew 17.2% to ₹5,034.73 lakh.

The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 26, 2026. N V C & Associates LLP, the statutory auditors, issued an audit report with an unmodified opinion on the financial statements. The financial results were prepared in accordance with Indian Accounting Standards (Ind-AS) and comply with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidated Performance

The group's total income for FY26 stood at ₹14,230.44 lakh, an increase from ₹13,263.76 lakh in the previous year. The profit before tax for the year decreased to ₹1,114.93 lakh from ₹1,341.06 lakh. The company operates two reportable segments: Pharmaceutical and Chemical Manufacturing. The Chemical Manufacturing segment reported a profit before tax of ₹1,368.56 lakh, while the Pharmaceutical segment reported a loss before tax of ₹253.63 lakh.

Standalone Results

On a standalone basis, the company reported a total income of ₹5,094.01 lakh for FY26, down from ₹5,386.81 lakh in the previous year. Total expenses increased to ₹5,295.14 lakh from ₹4,893.95 lakh. The company noted that other income for the previous year included a profit on the sale of Property, Plant, and Equipment amounting to ₹1,010.00 lakh, making the figures not comparable. Additionally, the company evaluated the implications of the new labour code, resulting in an incremental impact of ₹10.92 lakh charged to the profit and loss statement for employee benefits.

Financial Position

The consolidated total assets as of March 31, 2026, stood at ₹16,661.92 lakh, up from ₹14,794.82 lakh in the previous year. The company's equity attributable to shareholders of the holding company increased to ₹7,292.41 lakh from ₹7,050.59 lakh. Non-controlling interests stood at ₹4,955.23 lakh. The standalone total assets were reported at ₹7,353.73 lakh, with total equity decreasing to ₹5,443.41 lakh from ₹5,607.54 lakh.